Evidence map›Paper›PMID 31853829›Full record

ArticleMetabolic brain disease2020

Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition.

Rachel Polcyn, Mollie Capone, Denise Matzelle, Brittany Lueking, Aljoeson Walker, Elizabeth Kau, Azizul Haque, Naren Banik

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolic brain disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rachel PolcynDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Mollie CaponeDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Denise MatzelleDepartment of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St, MSC606, Charleston, SC, 29425, USA.
Brittany LuekingDepartment of Neurology, Medical University of South Carolina, Charleston, SC, USA.
Aljoeson WalkerRalph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Elizabeth KauRalph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA.
Azizul HaqueDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. haque@musc.edu.
Naren BanikDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. baniknl@musc.edu.ORCID http://orcid.org/0000-0001-9328-9365
Medical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

BLRD VA I01 BX002349BLRD VA I01 BX004269
6 · The paper itself

Abstract

This study examines the cytokine/chemokine profile of a 62-year-old African American male with progressive multiple sclerosis (MS). MRI images of the MS patient demonstrated generalized white matter involvement with multiple lesions in the periventricular area. A 42-plex Discovery Assay® (Eve Technologies) of the patient's plasma and peripheral blood mononuclear cells (PBMCs) supernatant or PBMC-derived T cell supernatant samples from two separate clinic visits revealed vastly differing cytokine/chemokine levels. In addition, certain cytokine/chemokine profiles had notable differences when compared to the larger patient group or patients' PBMCs treated with a calpain inhibitor in vitro. Interestingly, large numbers of cytokines/chemokines and growth factors in MS PBMCs are modulated by calpain inhibition, suggesting the clinical significance of these findings in designing better therapeutics against progressive MS.

Indexed as

BiomarkersCalpainChemokinesCytokinesGlycoproteinsHumansInterferon beta-1aMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveBiomarkersCalpaincalpain inhibitorsChemokinesCytokinesGlycoproteinsInterferon beta-1aCalpainCytokine/chemokinePBMCsProgressive multiple sclerosisT cells

Identifiers

PMID31853829
PMCPMC9773329
OpenAlexW2995217329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.